Applied Therapeutics, Inc. APLT
Set alert
At close · Jul 2
After hours · Jul 2, 4:00 PM ET
- YTD
- +3.00%
- 1 year
- -81.62%
- Open
- 0.103
- Prev close
- 0.103
- Mkt cap
- 99.09M
- Vol
- 0
- Avg vol
- 5.16M
- EPS
- -1.42
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.103
- High
- 0.103
- Forward P/E
- -1.85
- Beta
- 2.02
- Short ratio
- 3.25
- Inst. own
- 103.35%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 6.47
- 200-d avg
- 5.81
- 1y target
- 5.92
3M chart
Signals (7)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Jan 26, 2026 | 9 months ago |
| RSI: Oversold | Dec 12, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 4, 2025 | 11 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| RSI: Oversold | Nov 13, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bearish | Nov 6, 2025 | 12 months ago |
Key statistics
- Market cap
- 99.09M
- Enterprise value
- 5.51M
- Trailing P/E
- 0.00
- Forward P/E
- -1.85
- PEG ratio
- 0.00
- Price / sales
- -467.40
- Price / book
- 16.70
- EPS (TTM)
- -1.42
- Beta
- 2.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- -212.00K
- Revenue growth
- 0.00%
- Free cash flow
- -3.58M
- Total cash
- 98.87M
- Total debt
- 1.97M
- Return on equity
- 0.00%
- Shares outstanding
- 116.36M
- Short % of float
- 13.60%
- 50-day average
- 6.47
- 200-day average
- 5.81
Analyst view
Consensus: buy
- Target (low)
- 1.50
- Target (mean)
- 5.92
- Target (high)
- 13.00
- Strong buy0
- Buy3
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.19413.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.13 | -0.20 | -0.07 | -53.85% |
| Aug 7, 2024 | Jun 1, 2024 | -0.10 | -0.13 | -0.03 | -30.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.10 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.07 | -0.16 | -0.09 | -128.57% |
| May 9, 2024 | Mar 1, 2024 | -0.07 | — | — | — |
| Mar 6, 2024 | Dec 1, 2023 | -0.15 | -0.33 | -0.18 | -120.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | William Blair | down | Outperform | Market Perform |
| Dec 20, 2024 | RBC Capital | main | Sector Perform | Sector Perform |
| Dec 2, 2024 | UBS | down | Buy | Neutral |
| Nov 29, 2024 | Citigroup | main | Buy | Buy |
| Nov 29, 2024 | Baird | main | Outperform | Outperform |
| Nov 29, 2024 | RBC Capital | down | Outperform | Sector Perform |
About Applied Therapeutics, Inc.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- appliedtherapeutics.com
News
- Head to Head Contrast: Q32 Bio (NASDAQ:QTTB) & Applied Therapeutics (NASDAQ:APLT)
- Immuron (NASDAQ:IMRN) and Applied Therapeutics (NASDAQ:APLT) Financial Analysis
- Analyzing Cartesian Therapeutics (NASDAQ:RNAC) and Applied Therapeutics (NASDAQ:APLT)
- Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
- Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
- Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
- Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
- Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
- Why RF Industries Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
- Applied Therapeutics Inc. (NASDAQ:APLT) Short Interest Update
Your note
Sign in to keep a note on APLT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALEXANDRIA REAL ESTATE EQUITIES INC | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 4, 2024 | 0 |
| FUNTLEYDER LESLIE D | Chief Executive Officer | Stock Award(Grant) | Dec 18, 2024 | 427,911 |
| HOOKS CORWIN DALE | Officer | Stock Award(Grant) | Apr 11, 2024 | 300,000 |
| JOHNSON JOHN H. | Officer and Director | Stock Award(Grant) | Dec 18, 2024 | 500,000 |
| KANTER STACY J | Director | Stock Award(Grant) | Jun 5, 2024 | 108,000 |
| LERNER TEENA L. PH.D. | Director | Stock Award(Grant) | Jun 5, 2024 | 105,422 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | 9.06% | 10,541,528 | 8.98M | Sep 29, 2024 |
| Morgan Stanley | 8.51% | 9,904,530 | 8.43M | Sep 29, 2024 |
| VR Adviser, LLC | 8.44% | 9,825,000 | 8.37M | Sep 29, 2024 |
| Perceptive Advisors Llc | 6.88% | 8,005,000 | 6.82M | Sep 29, 2024 |
| Blackrock Inc. | 5.97% | 6,942,699 | 5.91M | Sep 29, 2024 |
| Franklin Resources, Inc. | 5.84% | 6,800,910 | 5.79M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 2.97% | 3,450,500 | 2.94M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.71% | 3,153,938 | 2.69M | Sep 29, 2024 |
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 2.42% | 2,817,505 | 2.40M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.14% | 2,486,153 | 2.12M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.57% | 1,830,616 | 1.56M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.99% | 1,151,026 | 980.21K | Sep 29, 2024 |